Truncated form of the Epstein-Barr virus protein EBNA-LP protects against caspase-dependent apoptosis by inhibiting protein phosphatase 2A

Journal of Virology

Volumn 81, Issue 14, 2007, Pages 7598-7607

  Garibal, Julie ^a   Hollville, Émilie ^a   Bell, Andrew I ^b   Kelly, Gemma L ^b   Renouf, Benjamin ^a   Kawaguchi, Yasushi ^c   Rickinson, Alan B ^b   Wiels, Joëlle ^a,d  

^a UMR 8126   (France)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF TOKYO   (Japan)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN EBNA LP; STAUROSPORINE; UNCLASSIFIED DRUG; VEROTOXIN 1; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; VIRUS CELL INTERACTION; VIRUS STRAIN;

APOPTOSIS; CASPASES; CELL LINE; HUMANS; PHOSPHOPROTEIN PHOSPHATASE; TRANSFECTION; VIRAL PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 34447270509     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02435-06     Document Type: Article

References (51)

1. Alfieri, C., M. Birkenbach, and E. Kieff. 1991. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology 181:595-608.
2. Alvarado-Kristensson, M., and T. Andersson. 2005. Protein phosphatase 2A regulates apoptosis in neutrophils by dephosphoryiating both p38 MAPK and its substrate caspase 3. J. Biol. Chem. 280:6238-6244.
3. Chen, W., and W. C. Hahn. 2003. SV40 early region oncoproteins and human cell transformation. Histol. Histopathol. 18:541-550.
4. Chen, W., R. Possemato, K. T. Campbell, C. A. Plattner, D. C. Pallas, and W. C. Hahn. 2004. Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 5:127-136.
5. Defrance, T. 2005. Mature B cells: apoptosis checkpoints. Transplantation 79:S4-S7.
6. Dufva, M., M. Olsson, and L. Rymo. 2001. Epstein-Barr virus nuclear antigen 5 interacts with HAX-1, a possible component of the B-cell receptor signalling pathway. J. Gen. Virol. 82:1581-1587.
7. Grasser, F. A., P. G. Murray, E. Kremmer, K. Klein, K. Remberger, W. Feiden, G. Reynolds, G. Niedobitek, L. S. Young, and N. Mueller-Lantzsch. 1994. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 84:3792-3798.
8. Gregory, C. D., M. Rowe, and A. B. Rickinson. 1990. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J. Gen. Virol. 71:1481-1495.
9. Han, I., S. Harada, D. Weaver, Y. Xue, W. Lane, S. Orstavik, B. Skalhegg, and E. Kieff. 2001. EBNA-LP associates with cellular proteins including DNA-PK and HA95. J. Virol. 75:2475-2481.
10. Harada, S., and E. Kieff. 1997. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J. Virol. 71:6611-6618.
11. Harmala-Brasken, A. S., A. Mikhailov, T. S. Soderstrom, A. Meinander, T. H. Holmstrom, Z. Damuni, and J. E. Eriksson. 2003. Type-2A protein phosphatase activity is required to maintain death receptor responsiveness. Oncogene 22:7677-7686.
12. Janssens, V., and J. Goris. 2001. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 353:417-439.
13. Jones, M. D., L. Foster, T. Sheedy, and B. E. Griffin. 1984. The EB virus genome in Daudi Burkitt's lymphoma cells has a deletion similar to that observed in a non-transforming strain (P3HR-1) of the virus. EMBO J. 3:813-821.
14. Kashuba, E., M. Yurchenko, K. Szirak, J. Stahl, G. Klein, and L. Szekely. 2005. Epstein-Barr virus-encoded EBNA-5 binds to Epstein-Barr virus-induced Fte1/S3a protein. Exp. Cell Res. 303:47-55.
15. Kawaguchi, Y., K. Nakajima, M. Igarashi, T. Morita, M. Tanaka, M. Suzuki, A. Yokoyama, G. Matsuda, K. Kato, M. Kanamori, and K. Hirai. 2000. Interaction of Epstein-Barr virus nuclear antigen leader protein (EBNA-LP) with HS1-associated protein X-1: implication of cytoplasmic function of EBNA-LP. J. Virol. 74:10104-10111.
16. Kelly, G., A. Bell, and A. Rickinson. 2002. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat. Med. 8:1098-1104.
17. Kelly, G. L., A. E. Milner, G. S. Baldwin, A. I. Bell, and A. B. Rickinson. 2006. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA 103:14935-14940.
18. Kelly, G. L., A. E. Milner, R. J. Tierney, D. S. Croom-Carter, M. Altmann, W. Hammerschmidt, A. I. Bell, and A. B. Rickinson. 2005. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J. Virol. 79:10709-10717.
19. Kennedy, G., J. Komano, and B. Sugden. 2003. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc. Natl. Acad. Sci. USA 100:14269-14274.
20. Kis, L. L., M. Takahara, N. Nagy, G. Klein, and E. Klein. 2006. IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines. Blood 107:2928-2935.
21. Kuppers, R. 2003. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat. Rev. Immunol. 3:801-812.
22. Lechward, K., O. S. Awotunde, W. Swiatek, and G. Muszynska. 2001. Protein phosphatase 2A: variety of forms and diversity of functions. Acta Biochim. Pol. 48:921-933.
23. Lee, J. M., K. H. Lee, C. J. Farrell, P. D. Ling, B. Kempkes, J. H. Park, and S. D. Hayward. 2004. EBNA2 is required for protection of latently Epstein-Barr virus-infected B cells against specific apoptotic stimuli. J. Virol. 78:12694-12697.
24. Li, H. P., and Y. S. Chang. 2003. Epstein-Barr virus latent membrane protein 1: structure and functions. J. Biomed. Sci. 10:490-504.
25. Ling, P. D., R. S. Peng, A. Nakajima, J. H. Yu, J. Tan, S. M. Moses, W. H. Yang, B. Zhao, E. Kieff, K. D. Bloch, and D. B. Bloch. 2005. Mediation of Epstein-Barr virus EBNA-LP transcriptional coactivation by Sp100. EMBO J. 24:3565-3575.
26. Mannick, J. B., J. I. Cohen, M. Birkenbach, A. Marchini, and E. Kieff. 1991. The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J. Virol. 65:6826-6837.
27. Mannick, J. B., X. Tong, A. Hemnes, and E. Kieff. 1995. The Epstein-Barr virus nuclear antigen leader protein associates with hsp72/hsc73. J. Virol. 69:8169-8172.
28. McCann, E. M., G. L. Kelly, A. B. Rickinson, and A. I. Bell. 2001. Genetic analysis of the Epstein-Barr virus-coded leader protein EBNA-LP as a coactivator of EBNA2 function. J. Gen. Virol. 82:3067-3079.
29. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683-765.
30. Nitsche, F., A. Bell, and A. Rickinson. 1997. Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain. J. Virol. 71:6619-6628.
31. Peng, C. W., Y. Xue, B. Zhao, E. Johannsen, E. Kieff, and S. Harada. 2004. Direct interactions between Epstein-Barr virus leader protein LP and the EBNA2 acidic domain underlie coordinate transcriptional regulation. Proc. Natl. Acad. Sci. USA 101:1033-1038.
32. Peng, R., A. V. Gordadze, E. M. Fuentes Panana, F. Wang, J. Zong, G. S. Hayward, J. Tan, and P. D. Ling. 2000. Sequence and functional analysis of EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptoviruses. J. Virol. 74:379-389.
33. Peng, R., S. C. Moses, J. Tan, E. Kremmer, and P. D. Ling. 2005. The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter. J. Virol. 79:4492-4505.
34. Peng, R., J. Tan, and P. D. Ling. 2000. Conserved regions in the Epstein-Barr virus leader protein define distinct domains required for nuclear localization and transcriptional cooperation with EBNA2. J. Virol. 74:9953-9963.
35. Rabson, M., L. Gradoville, L. Heston, and G. Miller. 1982. Non-immortalizing P3J-HR-1 Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye. J. Virol. 44:834-844.
36. Radhika, V., D. Onesime, J. H. Ha, and N. Dhanasekaran. 2004. Galpha13 stimulates cell migration through cortactin-interacting protein Hax-1. J. Biol. Chem. 279:49406-49413.
37. Rooney, C., J. G. Howe, S. H. Speck, and G. Miller. 1989. Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus. J. Virol. 63:1531-1539.
38. Rowe, D. T. 1999. Epstein-Barr virus immortalization and latency. Front. Biosci. 4:D346-D371.
39. Sample, J., M. Hummel, D. Braun, M. Birkenbach, and E. Kieff. 1986. Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. Proc. Natl. Acad. Sci. USA 83:5096-5100.
40. Shaku, F., G. Matsuda, R. Furuya, C. Kamagata, M. Igarashi, M. Tanaka, M. Kanamori, Y. Nishiyama, N. Yamamoto, and Y. Kawaguchi. 2005. Development of a monoclonal antibody against Epstein-Barr virus nuclear antigen leader protein (EBNA-LP) that can detect EBNA-LP expressed in P3HR1 cells. Microbiol. Immunol. 49:477-483.
41. Sharp, T. V., H. W. Wang, A. Koumi, D. Hollyman, Y. Endo, H. Ye, M. Q. Du, and C. Boshoff. 2002. K15 protein of Kaposi's sarcoma-associated herpesvirus is latently expressed and binds to HAX-1, a protein with antiapoptotic function. J. Virol. 76:802-816.
42. 1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J. 13:3321-3328.
43. Speck, S. H., A. Pfitzner, and J. L. Strominger. 1986. An Epstein-Barr virus transcript from a latently infected, growth-transformed B-cell line encodes a highly repetitive polypeptide. Proc. Natl. Acad. Sci. USA 83:9298-9302.
44. Szekely, L., K. Pokrovskaja, W. Q. Jiang, G. Selivanova, M. Lowbeer, N. Ringertz, K. G. Wiman, and G. Klein. 1995. Resting B-cells, EBV-infected B-blasts and established lymphoblastoid cell lines differ in their Rb, p53 and EBNA-5 expression patterns. Oncogene 10:1869-1874.
45. Szekely, L., G. Selivanova, K. P. Magnusson, G. Klein, and K. G. Wiman. 1993. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. USA 90:5455-5459.
46. Taga, S., K. Carlier, Z. Mishal, C. Capoulade, M. Mangeney, Y. Lecluse, D. Coulaud, C. Tétaud, L. L. Pritchard, T. Tursz, and J. Wiels. 1997. Intracellular signalling events in CD77-mediated apoptosis of Burkitt's lymphoma cells. Blood 90:2757-2767.
47. Tang, D., J. M. Lahti, and V. J. Kidd. 2000. Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis. J. Biol. Chem. 275:9303-9307.
48. Tetaud, C., T. Falguieres, K. Carlier, Y. Lecluse, J. Garibal, D. Coulaud, P. Busson, R. Steffensen, H. Clausen, L. Johannes, and J. Wiels. 2003. Two distinct Gb3/CD77 signaling pathways leading to apoptosis are triggered by anti-Gb3/CD77 MAb and verotoxin-1. J. Biol. Chem. 278:45200-45208.
49. Van Hoof, C., and J. Goris. 2003. Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question. Biochim. Biophys. Acta 1640:97-104.
50. Young, L. S., and P. G. Murray. 2003. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22:5108-5121.
51. Young, L. S., and A. B. Rickinson. 2004. Epstein-Barr virus: 40 years on. Nat Rev. Cancer 4:757-768.